The roles of life sciences, pharma companies and those of data-technology companies have been orbiting around disease prevention, patient pathways, hospital delivery efficiencies and long-term care. Has the pandemic created a more conducive synergy. Where one starts and the other finishes shouldn’t really matter now, should it?